Pharmaceutical Pricing and Medical Innovation
Featured Topics
Lead story
Other featured articles
-
Minimally Invasive Surgeries Offer Strategies for Hospitals to Create Surge Capacity
While COVID-19 hospitalizations are down, a new Schaeffer Center white paper highlights the importance of investing in minimally invasive technologies that will allow hospitals to prepare for future surges.
Posted in -
Reassessing the Value of Minimally Invasive Technologies in the Era of COVID-19
This Schaeffer Center white paper highlights the importance of investing in minimally invasive technologies that will allow hospitals to prepare for future surges.
Posted in -
Schaeffer Solutions: Health Policy Recommendations for the Biden Administration and 117th U.S. Congress
The USC-Brookings Schaeffer Initiative for Health Policy has developed practical recommendations and analysis in a number of critical policy areas.
Posted in -
Create a U.S. Institute of Health Technology Assessment to Preserve Innovation and Control Costs
Americans need affordable, accessible and innovative health care. An important first step that can be taken without risking heavy-handed intervention is for Congress to establish an independent Institute of Health Technology Assessment.
About this section
High pharmaceutical prices may garner headlines, but innovation must be appropriately incentivized to help solve healthcare’s intractable challenges. The Schaeffer Center connects industry, the academy and government to support the scientific and technological creativity that saves and improves lives — and spurs economic growth.
Our Experts On Pharmaceutical Pricing and Medical Innovation
Our Work In Pharmaceutical Pricing and Medical Innovation
-
USC Schaeffer Center and Aspen Institute Advisory Panel Recommend Ways to Modernize Health Technology Assessment in the U.S.
The U.S. has no public organization dedicated to producing and evaluating HTAs despite the potential of HTAs providing critical input about price and value, while also recognizing the contribution of innovation to advancing health and healthcare.
-
Health Technology Assessment in the U.S. – A Vision for the Future
Health technology assessment (HTA) can help achieve the dual health policy goals of ensuring affordability and encouraging innovation.
Categorized in -
Monthly Cost Sharing Doubles Throughout the Year for Some Medicare Insulin Users
Schaeffer Center researchers examined how use of insulin changes as cost-sharing fluctuates over the course of the year for Medicare Part D beneficiaries.
-
Without Reform, Medicare Policies Will Hamstring New Gene Therapies
It took until the fall of 2020 for Medicare to consistently pay an adequate amount for CAR-T therapy. Now that same agonizing process awaits a raft of promising gene therapies in the pipeline – with lives in the balance – unless policymakers take action.
Categorized in -
Paying for Cell and Gene Therapies in Medicare
Join Schaeffer Center Director Dana Goldman in conversation with Jeet Guram and Kathy Buto about policy lessons learned and potential solutions to support innovation and patient access in cell and gene therapies.
Categorized in -
Blood-Based Multicancer Tests Could Help Reduce Racial and Socioeconomic Cancer Health Disparities
Out of the 1.3 million individuals between the ages of 50-79 who are diagnosed with cancer, only 15% of those cases will be caught early. Aspen Institute and USC Schaeffer Center partnered for an expert discussion on early detection technologies.